Free Trial

What's Behind Walgreens Stock Plunge: What Investors Can Do Next

walgreens logo sign on storefront

Key Points

  • Shares of Walgreens are down over 25% in a single day as management points to the closure of several locations.
  • The difference between Walgreens and its competitor, CVS, is found in this financial metric.
  • One lateral play can be considered for maximum income potential without as much risk as markets think.
  • 5 stocks we like better than CVS Health.

After years of a downtrend in their price, shares of Walgreens Boots Alliance Inc. NASDAQ: WBA have thrown in the towel this time. In a single day, the stock is down over 25% in a sign that can’t be taken in any other way than a ‘run’ message. However, some remain hopeful about the stock recovering, but that would be severely disconnected from current fundamentals.

Walgreens Boots Alliance Today

Walgreens Boots Alliance, Inc. stock logo
WBAWBA 90-day performance
Walgreens Boots Alliance
$9.19 -0.11 (-1.18%)
(As of 12/24/2024 05:19 PM ET)
52-Week Range
$8.08
$27.05
Dividend Yield
10.88%
Price Target
$12.58

Today, investors get a chance to audit the main drivers behind Walgreens and come to a better-educated conclusion as to whether the stock is worth keeping on a watchlist. More specifically, investors should watch the developments between Walgreens and its main competitor, CVS Health Co. NYSE: CVS, because the trends could not be more apparent.

Last but not least, savvy investors understand that it isn’t just Walgreens and CVS at stake in this turbulent time but also entities that back Walgreens locations, such as its landlords. According to the saying, one man’s trash is another man’s treasure, so here is how to figure out where the real treasure hunt will end up.

Walgreens vs. CVS: Financials Break Down the Competition

There is, of course, a good reason for the price crash on shares of Walgreens, and it’s got everything to do with the company’s financials. For starters, investors can break apart the latest quarterly results to figure out what happened behind the scenes.

While the company’s press release points to earnings per share (EPS) nearly quadrupling, the reality couldn’t be further. Therefore, net income and EPS can be easily manipulated. In contrast, other metrics like free cash flow (operating cash flow minus capital expenditures) cannot.

This is why investors should focus on that instead, and here’s what they would find: a net operating outflow of $314 million, minus $1.1 billion in capital expenditures, for a negative free cash flow of over $1.3 billion. Since a company cannot run without cash flow, seeing what management did next makes sense.

The plan is to close a ‘significant’ amount of Walgreens locations, assuming they are unprofitable. While this could free up some cash and cut overhead expenses, it won’t be enough to offset the unprofitable operations that lie at the heart of the company.

Because Walgreens has no free cash flow, it cannot fund its operations further without taking on debt or diluting shareholders. Because of this, the stock’s 8.2% dividend yield should be nothing short of a red flag to investors, a bait to avoid.

Walgreens Boots Alliance Dividend Payments

Dividend Yield
10.88%
Annual Dividend
$1.00
Annualized 3-Year Dividend Growth
1.25%
Dividend Payout Ratio
-9.99%
Recent Dividend Payment
Dec. 12
WBA Dividend History

On the other hand, here’s what can be said about CVS’s financials. The company’s latest quarterly results show investors operating cash flow of $4.9 billion, leaving them with positive free cash flow even after $705 million in capital expenditures. What management chose to do with this capital was also the right thing.

Up to $3 billion was set aside to repurchase stock, compounding the upside effects for existing shareholders. This trend must be why analysts at J.P. Morgan Chase saw it fit to boost CVS’s valuations to $86 a share, daring it to rally by 47.2% from where it sits today.

Now that the dust is settled, investors can zoom out of this dramatic price action and find themselves with the next best thing, Walgreens’ landlord Realty Income Co. NYSE: O, a real estate investment trust (REIT) known for paying monthly dividends instead of quarterly.

The Best Income a Dip Can Buy: Realty Income Stock

As Walgreens’ landlord, Realty Income stock is exposed to the closure of hundreds of locations. However, markets habitually exaggerate things, so here’s just how exposed they really are.

Walgreens Boots Alliance MarketRank™ Stock Analysis

Overall MarketRank™
84th Percentile
Analyst Rating
Reduce
Upside/Downside
36.9% Upside
Short Interest Level
Bearish
Dividend Strength
Moderate
Environmental Score
-2.09
News Sentiment
0.42mentions of Walgreens Boots Alliance in the last 14 days
Insider Trading
N/A
Proj. Earnings Growth
-4.58%
See Full Analysis

According to Realty Income’s latest quarter, the company only derived 3.4% of its rental income from Walgreens. This is not significant enough to justify a more than 1% sell-off in an otherwise low-volatility stock.

When the market realizes how little this event means for Realty Income, it will be too late for investors to squeeze a potential discount. Speaking of discounts, the stock’s valuation is so low that its annual dividend yield has jumped to 6%, the highest in company history (excluding COVID sell-offs).

According to those at Stifel Nicolaus, Realty Income stock is worth up to $65 a share, daring it to rally by as much as 24% from where it trades today. More than that, Wall Street still expects to see 3.8% EPS growth in Realty Income this year, keeping up with inflation and GDP growth.

→ The #1 Coin for November 2024 (From Crypto 101 Media) (Ad)

Should you invest $1,000 in CVS Health right now?

Before you consider CVS Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.

While CVS Health currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report
Gabriel Osorio-Mazilli
About The Author

Gabriel Osorio-Mazilli

Contributing Author

Value Stocks, Asian Markets, Macro Economics

Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Realty Income (O)
4.1778 of 5 stars
$53.24+0.5%5.94%50.71Hold$63.23
Walgreens Boots Alliance (WBA)
4.2067 of 5 stars
$9.19-1.2%10.88%-0.92Reduce$12.58
CVS Health (CVS)
5 of 5 stars
$44.25+0.2%6.01%11.23Moderate Buy$69.12
Compare These Stocks  Add These Stocks to My Watchlist 


Featured Articles and Offers

Recent Videos

Why Energy Stocks Are Poised for Explosive Growth in 2025
From Landfills to Profits: Opal Fuels CEO Shares How the Company Turns Trash into Cash
The Real Reason Tesla Stock Is Soaring – and Why Tech Expert Says It Won’t Stop

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines